

Docket No.: 03818/1200029-US2

(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:

Dieter Soll

Application No.: 10/661,399

Filed: September 12, 2003

For: GlutRNAGLN AMIDOTRANSFERASE - A

NOVEL ESSENTIAL TRANSLATIONAL

COMPONENT

Confirmation No.: 8426

Art Unit: N/A

Examiner: Not Yet Assigned

STATEMENT PURSUANT TO 37 CFR 1.821(f)

MS Sequence Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

Submitted herewith for filing in connection with the above-referenced patent application is a labeled, computer readable copy of the Sequence Listing included in the application.

The sequence information in paper copy of the Sequence Listing contained on pages 1 to 18 of said Sequence Listing, as required by 37 CFR 1.821(c), and the sequence information in computer readable form of the Sequence Listing described above, as required by 37 CFR 1.821(e), are the same as required by 37 CFR 1.821(f).

Early favorable consideration of the patent application is respectfully solicited.

Dated: October 28, 2004

Respectfully submitted,

Flynn Barrison

Registration No.: 53,970 DARBY & DARBY P.C.

P.O. Box 5257

New York, New York 10150-5257

(212) 527-7700

(212) 753-6237 (Fax)

Attorneys/Agents For Applicant